The immunoexpression of EGFR, HER2 and HER3 in malignant serous ovarian tumors

Vol. 58 No. 4, 2017


Andreea-Elena Cirstea, Alex Emilian Stepan, Claudiu Margaritescu, Roxana Eugenia Zavoi, Daniel Alin Olimid, Cristiana Eugenia Simionescu

The expression of epidermal growth factor (EGF) receptors is common in human carcinomas and the proteins are used as therapeutics targets. In this study, we analyzed the immunoexpression of EGFR, HER2 (EGFR2) and HER3 (EGFR3) in 41 cases of serous borderline ovarian tumors and carcinomas, in relation to the degree of differentiation and tumor stage. The quantification of the results was done using the final staining score (FSS), which took into account the number of labeled cells and the intensity of immunoreactions. For all the receptors, the FSS values corresponding to the high-grade serous carcinomas were significantly superior compared with low-grade carcinomas and borderline tumors. Also, the FSS values associated with advanced stages ovarian tumors were significantly superior compared to those in the initial stages. In this study, we found positive linear correlations between the values associated with the expression of EGF receptors. The relation of EGFR, HER2 and HER3 immunoexpression with the lesion subtype, tumor grade and stage, designates the EGF receptors system as possible therapeutic target in ovarian serous tumors.

Corresponding author: Alex Emilian Stepan, Lecturer, MD, PhD; e-mail:

Download PDF
Download cover
Download contents

Journal archive